Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Fig. 1

PFS by biomarker status. a T-DM1 versus control. b T-DM1 plus pertuzumab versus control. c T-DM1 plus pertuzumab versus T-DM1. CI confidence interval, HER human epidermal growth factor receptor, HR unstratified hazard ratio, PFS progression-free survival, PI3K phosphoinositide 3-kinase, PTEN phosphatase and tensin homolog, T-DM1 trastuzumab emtansine. *PI3K and PTEN category “other” represents patients with no PI3K mutation and no decrease in PTEN, or one of these in combination with an unknown for the other marker (e.g., no PI2K mutation and unknown PTEN status)

Back to article page